文献速递淋巴瘤造血干细胞移植与细胞治疗

风险适应性预防性托珠单抗降低CTL019后严重细胞因子释放综合征的前瞻性临床试验

Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.
PubMed 文献 · J Clin Oncol · 2021-01-08

该前瞻性试验评估风险适应性预防性托珠单抗(PT)预防CTL019后重度CRS的效果。根据肿瘤负荷分组,高负荷组出现持续高热后接受单次PT。高负荷组4级CRS发生率为27%(95%CI 8-55),达到主要终点,且未影响抗肿瘤疗效。

要点

  • 高肿瘤负荷患者预防性使用托珠单抗后4级CRS发生率为27%。
  • 预防性托珠单抗未 adversely 影响CTL019的疗效或安全性。
  • 高肿瘤负荷组无事件生存和总生存较差。

核心结论

  • 风险适应性预防性托珠单抗给药降低了预期4级CRS发生率,达到研究终点。
  • 该干预未对CTL019的抗肿瘤疗效或安全性产生不良影响。

研究设计与样本

  • 根据骨髓涂片或活检肿瘤负荷分为高负荷组(≥40%,15例)和低负荷组(<40%,55例)。
  • 高负荷组在高持续发热后接受单次托珠单抗(8-12 mg/kg),低负荷组接受标准CRS管理。
  • 主要终点为4级CRS(Penn量表)频率,高负荷组观察到≤15例中5例定义为临床有意义。

主要发现

  • 高负荷组4级CRS发生率为27%(95%CI 8-55),低负荷组为3.6%(95%CI 0.4-13)。
  • 高负荷组最佳总缓解率为87%,低负荷组为100%。
  • 高负荷组CTL019初始扩增高于低负荷组(P < .001),但持久性无差异(P = .73)。
  • 高负荷组无事件生存和总生存较差(P = .004和P < .001)。
  • 事后分析中,预防性托珠单抗组与既往I期队列4级CRS发生率分别为27%和50%(P = .18)。

关键数值与推荐

  • 高负荷组肿瘤负荷定义为骨髓涂片或活检中≥40%。
  • 预防性托珠单抗剂量为8-12 mg/kg单次给药。
  • 主要终点4级CRS(Penn量表)高负荷组观察到≤15例中5例为临床有意义。

临床怎么用

  • 对高肿瘤负荷的CD19 CAR-T治疗患者,可在出现高持续发热后预防性使用托珠单抗以降低4级CRS风险。
  • 预防性托珠单抗未影响抗肿瘤疗效,但高负荷组生存仍较差,需关注长期结局。

局限性

  • 事后分析比较为历史对照,非随机对照。
  • 样本量较小,高负荷组仅15例。
  • 单中心前瞻性研究,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To prospectively evaluate the effectiveness of risk-adapted preemptive tocilizumab (PT) administration in preventing severe cytokine release syndrome (CRS) after CTL019, a CD19 chimeric antigen receptor T-cell therapy. METHODS: Children and young adults with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia were assigned to high- (≥ 40%) or low- (< 40%) tumor burden cohorts (HTBC or LTBC) based on a bone marrow aspirate or biopsy before infusion. HTBC patients received a single dose of tocilizumab (8-12 mg/kg) after development of high, persistent fevers. LTBC patients received standard CRS management. The primary end point was the frequency of grade 4 CRS (Penn scale), with an observed rate of ≤ 5 of 15 patients in the HTBC pre-defined as clinically meaningful. In post hoc analyses, the HTBC was compared with a historical cohort of high-tumor burden patients from the initial phase I CTL019 trial. RESULTS: The primary end point was met. Seventy patients were infused with CTL019, 15 in the HTBC and 55 in the LTBC. All HTBC patients received the PT intervention. The incidence of grade 4 CRS was 27% (95% CI, 8 to 55) in the HTBC and 3.6% (95% CI, 0.4 to 13) in the LTBC. The best overall response rate was 87% in the HTBC and 100% in the LTBC. Initial CTL019 expansion was greater in the HTBC than the LTBC (P < .001), but persistence was not different (P = .73). Event-free and overall survival were worse in the HTBC (P = .004, P < .001, respectively). In the post hoc analysis, grade 4 CRS was observed in 27% versus 50% of patients in the PT and prior phase I cohorts, respectively (P = .18). CONCLUSION: Risk-adapted PT administration resulted in a decrease in the expected incidence of grade 4 CRS, meeting the study end point, without adversely impacting the antitumor efficacy or safety of CTL019.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kadauke S, Myers RM, Li Y, et al. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. J Clin Oncol. 2021. PMID: 33417474. doi:10.1200/JCO.20.02477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。